Evidence map›Paper›PMID 40545764›Full record

ReviewBiomarkers in medicine2025

Elucidating the multifaceted role and therapeutic potential of Sulf-2 in human tumor biology.

Huanyan Peng, Man Liu, Songkang Liu, Chun Ning, Dongye Yang

Abstract readReview
In one paragraph

Review in Biomarkers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Huanyan PengDivision of Gastroenterology & Hepatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, P.R. China.ORCID 0009-0003-8747-4830
Man LiuLaboratory of Molecular Biology, Henan Luoyang Orthopedic Hospital (Henan Provincial Orthopedic Hospital), Zhengzhou, Henan, P.R. China.
Songkang LiuDivision of Gastroenterology & Hepatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, P.R. China.
Chun NingDivision of Gastroenterology & Hepatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, P.R. China.
Dongye YangDivision of Gastroenterology & Hepatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sulf-2, a key member of the sulfatase family, regulated tumor progression, invasion, and metastasis through various mechanisms including genetic alterations, epigenetic modifications, transcriptional regulation, and microenvironmental influences. The dysregulation of Sulf-2 has been implicated as a pivotal driver in the development of numerous tumors. The lack of a comprehensive understanding of Sulf-2 enzymatic activities has limited the advancement of research progress, largely due to the intricate modulation of heparan sulfate (HS) biology by this enzyme. In this review, we will comprehensively discuss the structure, function, and regulatory mechanisms of Sulf-2, elucidated the mechanisms of Sulf-2 in different human-type tumors. Furthermore, we would summarize the potential applications and limitations of Sulf-2 as a target in combining therapies for human tumors, providing insights that could be instrumental in advancing targeted cancer treatments. Our comprehensive review will shed light on the multifaceted role and therapeutic potential of Sulf-2 in human tumor biology.

Indexed as

NeoplasmsSulfotransferasesGene Expression Regulation, NeoplasticHumansSulfatasesSULF2 protein, humanSulfatasesSulfotransferasesenzymatic activitiesheparan sulfate (HS)human tumormultifaceted rolesSulf-2therapeutic target

Identifiers

PMID40545764
PMCPMC12233869

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.